FIGURE 6.

TQ demonstrates potent antitumor effect in multiple myeloma in vivo models. A, Survival of DP42-bearing mice treated with TQ (30 mg/kg/day, n = 8) or vehicle control (VC, n = 5). B, Growth kinetics of human H929 subcutaneous tumors established in C.B-17 SCID mice and treated with TQ (n = 4) or VC (n = 4). C, Growth kinetics of human RPMI8226 subcutaneous tumors established in NSG mice and treated with TQ (n = 5) or VC (n = 4). D, Human MM RPMI8226 or MM1.S tumors were established in NSG mice by intravenous injection of 5 × 10⁶ tumor cells. Treatment with TQ or VC started on day 14 after tumor cell injection. Survival of mice was determined. n = 5 per group. Statistics: two-way ANOVA (B and C) or log-rank test (A and D). E–G, Human multiple myeloma H929 tumors were established in NSG mice by subcutaneous injection of 5 × 10⁶ cells. Mice were split into groups and given either TQ, lenalidomide (LEN, E), bortezomib (F), or ixazomib (IXA, G) as monotherapy or in combination with TQ. Kinetics of tumor growth (left) and tumor growth rate (right) are shown. Statistics: ANOVA with Tukey multiple comparisons test.